Standing Committee on Ethics (SCE) meeting highlights: December 1-2, 2016

Issues discussed at the SCE

  • CIHR's Strategic Framework on Equity
    The SCE was informed of CIHR's Strategic Framework and related proposed actions on equitable access to CIHR funding. The SCE was supportive of the evidence-based Framework and Action Plan, and provided comments for consideration.
  • Equity and Personalized Health (PH)
    The SCE was asked for advice on how to enhance integration of considerations of equitable access to benefits into future CIHR investments in the PH Initiative. The SCE agreed that integrating considerations of equity into the PH initiative, and in priority-driven research more generally, was important. The SCE plans to develop indicators around equity considerations for use by Science Council.
  • Revisions to the Tri-Council Policy Statement: Ethical Conduct for Research involving Humans 2nd edition (TCPS 2)
    The Secretariat on Responsible Conduct of Research presented the proposed revisions to TCPS 2 from the Panel on Research Ethics. These revisions are under public consultation through January 2017. The SCE was supportive of the proposed changes to TCPS 2 overall, and recognized the enormous amount of hard work involved in making TCPS 2 a living document. The SCE will provide specific comments on the proposed changes to TCPS 2 during the consultation period.
  • Ethics of Patient Engagement
    The SCE was updated on the CIHR project on Ethics in Patient Engagement in Research, including the Working Group's Terms of Reference and proposed key elements of ethical guidance to be developed into a document for broad consultation. The SCE was supportive of the project.


  • The SCE Chair reported that the Governing Council approved the appointment of the following new members: Dr. Chelsea Gabel, Assistant Professor in the Department of Health, Aging and Society and the Indigenous Studies Program at McMaster University; Dr. Fern Brunger, a member of the CIHR Institute Advisory Board on Research Excellence, Policy and Ethics, and Associate Professor of Health Care Ethics in the Faculty of Medicine at Memorial University; and Dr. Jennifer Hamilton, Senior Director, New Ventures (Canada) for Johnson & Johnson Innovation.
Date modified: